The patients suitability is a key factor as is the expertise of the professional performing the treatments
Whether you are already using tirzepatide and considering adding AOD 9604, or you are researching this stack from scratch, this guide covers the mechanisms, the protocols, the safety data, and the practical details that most resources skip entirely
Providers should transition to emerging weight loss peptides when a patient experiences intractable side effects (like severe nausea or gastroparesis), when they hit a hard weight loss plateau despite dietary compliance, or when the primary clinical obstacle is documented cellular metabolic resistance rather than hyperphagia (overeating)
Do not directly apply to your skin
Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded